Clinical trials: Stage IIB Breast Cancer
Metastatic Breast Cancer
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients
This phase I/II study is designed to compare different treatment schedules of a personalized anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion with intra-tumor immunotherapy.
- Trial name
- MBC (NCT02018419)
- Testing
- AlloStim, Cryoablation
- Where
- United States
- Sponsor
- Mirror Biologics, Inc.
Adenocarcinoma Breast Stage IV
IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma
The proposed Phase IIb clinical study aims to investigate the safety and efficacy of the active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic…
- Trial name
- NCT02614833
- Testing
- IMP321 (eftilagimod alpha), Paclitaxel
- Where
- 29 sites in Belgium, France and 5 more
- Volunteers
- 242 people
- Sponsor
- Immutep S.A.S.
Neoplasms, Breast
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
- Trial name
- CHERLOB (NCT00429299)
- Testing
- lapatinib, trastuzumab, paclitaxel
- Where
- 17 sites in Germany, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer, Stage IV Breast Cancer
BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether BP-C1 is effective in the short-term treatment of metastatic breast cancer patients who have previously undergone at least three lines of chemotherapy.
- Trial name
- NCT03603197
- Testing
- BP-C1
- Where
- 4 sites in Thailand
- Volunteers
- 38 people
- Sponsor
- Meabco A/S
Breast Cancer
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
This is a phase IIb, randomized, parallel-group, noncomparative, multicenter, pilot study designed to evaluate the safety and efficacy of bevacizumab with or without (+/-) trastuzumab administered with three different…
- Trial name
- NCT00365365
- Testing
- Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Sanofi
Breast Cancer
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast…
- Trial name
- NCT01077154
- Testing
- Denosumab
- Where
- 459 sites in United States, Argentina and 37 more
- Volunteers
- 4,509 people
- Sponsor
- Amgen
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi
Metastatic Triple-negative Breast Cancer
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
The goal of this study is to learn more about the effectiveness of the study drug, sacituzumab govitecan-hziy, in Chinese participants with metastatic triple-negative breast cancer (mTNBC) who received at least 2 systemic…
- Trial name
- NCT04454437
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 17 sites in China
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences
Breast Adenocarcinoma, Estrogen Receptor Positive
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients…
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma
- Trial name
- NCT01697293
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Prescient Therapeutics, Ltd.
Chemotherapy-induced Neutropenia
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Evaluation of the efficacy and safety of recombinant human serum albumin / granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced neutropenia
- Trial name
- NCT03251768
- Testing
- rHSA-GCSF 2.4mg, GCSF
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Breast Cancer
Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers
This study will assess optimal duration of pre-operative treatment with letrozole and to correlate clinical efficacy with appropriate surrogate markers.
- Trial name
- NCT00535418
- Testing
- Letrozole
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Evaluate Safety, Efficacy and Pharmacokinetics
The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)
- Trial name
- Compare (NCT01084863)
- Testing
- CT-P6, Herceptin, Paclitaxel
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- Celltrion
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast…
- Trial name
- NCT07544056
- Testing
- BEBT-209 capsules, Carboplatin Injection, Gemcitabine Hydrochloride for Injection
- Where
- 2 sites in China
- Volunteers
- 446 people
- Sponsor
- BeBetter Med Inc
Metastatic Breast Cancer, Stage IV Breast Cancer
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether BP-C1 is effective in the treatment of metastatic breast cancer patients who had previously received at least three lines of chemotherapy.
- Trial name
- NCT02783794
- Testing
- BP-C1
- Where
- 6 sites in Russia, Thailand
- Volunteers
- 36 people
- Sponsor
- Meabco A/S